PROCEPT BioRobotics (US:PRCT)2026-02-25 22:30Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $76.4 million, representing a 12% year-over-year growth [11] - U.S. revenue for the quarter was $66.6 million, reflecting a 10% growth compared to the prior year [11] - Gross margin for Q4 2025 was 60.6%, down from 64% in Q4 2024, primarily due to lower-than-expected U.S. consumable revenue and a one-time voluntary field action [13] - Net loss for Q4 2025 was $29.8 million, compared to a net loss of $18.9 million in Q4 2024 [14] - Adjusted EBITDA was a loss of $19 million in Q4 2025, compared to a loss of $10.3 million in the prior year [14] Business Line Data and Key Metrics Changes - Approximately 12,200 U.S. procedures were completed in Q4 2025, representing a 69% year-over-year growth [11] - Handpieces sold totaled 9,400 units at an average selling price of approximately $3,340, reflecting a 5% price increase compared to Q3 2025 [11] - Total U.S. handpiece and other consumable revenue was $34 million in Q4 2025, representing a 16% growth compared to Q4 2024 [12] - 65 new HYDROS systems were sold in Q4 2025, with an installed base of 718 systems, a 42% increase compared to year-end 2024 [12] Market Data and Key Metrics Changes - International revenue in Q4 2025 was $9.8 million, representing year-over-year growth of 25% [12] - The company expects 2026 total U.S. procedures to be in the range of 60,000-64,000, representing growth of approximately 39%-48% [15] Company Strategy and Development Direction - The company is focusing on increasing procedure volume, expanding margins, and achieving profitability while gaining market share [4] - A new integrated regional structure for the commercial team has been established to ensure better coordination around customer success and procedure growth [5] - A dedicated launch team has been formed to drive consistent launches and improve downstream utilization [5] Management's Comments on Operating Environment and Future Outlook - Management acknowledged that the financial performance in Q4 was lower than anticipated but emphasized that the changes made are critical for sustainable high growth and a clear path to profitability [19] - The company is confident in its long-term growth and profitability trajectory through 2026 and 2027 despite short-term disruptions [16] - Management expects to see benefits from the sales force realignment in the second half of the year [27] Other Important Information - The company has reset its 2026 guidance to $390 million-$410 million, representing annual growth of 27%-33% [9] - The average selling price for handpieces is expected to increase to $3,500 in 2026 [16] - The company plans to provide a detailed multi-year look at its financial guidance during the upcoming Investor Day [10] Q&A Session Summary Question: What unfolded in Q4 regarding handpiece sales? - Management indicated that the softness in handpiece sales was influenced by customer purchasing behavior and the elimination of bulk purchase discounts [21][22] Question: Why is there confidence in back-end loaded growth for 2026? - Management explained that the sales force's maturity and the new alignment would take time but are expected to yield benefits in the latter half of the year [27] Question: What gives confidence in a 1-to-1 ratio of handpiece sales to procedures in 2026? - Management noted that historical data showed handpiece sales were typically higher than procedure volumes, but recent changes are expected to align them more closely [31][32] Question: Are there concerns about customer dissatisfaction due to the end of bulk purchase deals? - Management does not anticipate dissatisfaction and believes that ordering patterns will stabilize without bulk discounts [39] Question: What is the health of underlying demand for procedures? - Management reported strong procedure growth of nearly 70% year-over-year, indicating healthy demand despite revenue shortfalls due to customer ordering behavior [52][53]